𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Serial neurophysiological studies of intramuscular botulinum-A toxin in humans

✍ Scribed by John A. Hamjian; Francis O. Walker


Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
706 KB
Volume
17
Category
Article
ISSN
0148-639X

No coin nor oath required. For personal study only.

✦ Synopsis


To characterize the time course of intramuscular botulinum toxininduced paresis, we serially performed electrophysiological measurements and recorded the sonographic size of an extensor digitorum brevis (EDB) muscle in 10 human subjects before and after injecting the EDB with 10 units of botulinum-A toxin. All EDB CMAPs decreased within 48 h, with peak decline at day 21 (8.3 f 3.1 mV to 3.0 f 0.9 mV). Decline of mean rectified voltage during maximal voluntary contraction of the EDB paralleled the change in CMAP amplitude. Average decrements to 2-Hz repetitive stimulation never exceeded 6% (day 42) and exercise failed to facilitate significantly CMAP amplitude. Atrophy peaked at day 42. The F-wave to M-wave ratio increased at day 2; silent periods did not change. Our findings confirm a primary peripheral action of the toxin, but a superimposed, transient central effect of the drug cannot be excluded. Intramuscular injections into EDB provide a useful model for studying chemodenervation effects.


πŸ“œ SIMILAR VOLUMES


Botulinum toxin treatment of muscle cram
✍ Dr Laura Bertolasi; Alberto Priori; Giuliano Tomelleri; Luigi G. Bongiovanni; Em πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 574 KB

## Abstract Botulinum toxin is now widely used in the treatment of severla hyperkinetic movement disorders. To evaluate its efficacy in treating muscle cramping syndromes, we studied clinical and neurophysiological variables before and after botulinum toxin injections into calf muscles and small fl

How muscles recover from paresis and atr
✍ Jian Shen; Jianjun Ma; Cassandra Lee; Beth P. Smith; Thomas L. Smith; Kim H. Tan πŸ“‚ Article πŸ“… 2006 πŸ› Elsevier Science 🌐 English βš– 408 KB

## Abstract Botulinum toxin A (BoNT‐A) is a potent biological toxin widely used for the management of skeletal muscle spasticity or dynamic joint contracture. Intramuscular injection of BoNT‐A causes muscle denervation, paresis, and atrophy. This clinical effect of botulinum toxin A lasts 3 to 6 mo

BotB (botulinum Toxin type B): Evaluatio
✍ Dr. Daniel D. Truong; Paul A. Cullis; Christopher F. O'Brien; Martin Koller; Tim πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 314 KB

## Abstract Botulinum toxin (BTX) injection is considered the treatment of choice for patients with cervical dystonia (torticollis). We conducted a pilot, open‐label, dose‐escalation study with BTX type B in 12 patients who no longer responded clinically to injections with BTX type A. At the doses